Daiichi Sankyo is committed to expanding scientific knowledge about edoxaban, as demonstrated through our research program evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings in atrial fibrillation (AF) and venous thromboembolism (VTE) designed to further build on the results of the pivotal ENGAGE AF and Hokusai-VTE studies.
The goal of EDOSURE is to generate new clinical and real-world-data regarding the use of edoxaban in AF and VTE populations, providing physicians and patients worldwide with greater treatment assurance.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 randomized, controlled trials, registries and non-interventional studies, including completed, ongoing and future research.
Edoxaban Studies in EDOSURE
AF patients undergoing electrical cardioversion
AF patients undergoing PCI
AF patients undergoing catheter ablation of AF
AF patients undergoing transcatheter aortic valve implantation (TAVI)
80 years or older Japanese AF patients who are ineligible for current OAC therapy
Patients with cancer and an acute VTE event
Edoxaban treatment in routine clinical practice in AF
Edoxaban treatment in routine clinical practice in VTE
Edoxaban management in diagnostic and therapeutic procedures in AF/VTE
Prevention of thromboembolic events in European Registry in AF patients
All Nippon AF In Elderly Registry in Japan (in more than 75 years in Japan)
Multicentre prospective registry in VTE patients with cancer
AF: atrial fibrillation, OAC: oral anticoagulant, PCI: Percutaneous Coronary Intervention, TAVI: transcatheter aortic valve implantation, VKA: vitamin K antagonist, VTE: venous thromboembolism